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Immunoglobulin heavy chain (IgH) expression and Ig secretion is inhibited by the 
environmental contaminant 2,3,7,8-tetrachlorodibenzo-ρ-dioxin (TCDD).  Within the IgH 
gene, the 3’ IgH regulatory region (3’IgH RR) has been identified as a transcriptional 
target of TCDD.  The 3’IgH RR, which in part regulates transcription of the IgH gene, is 
composed of four enhancers in the mouse: hs3a; hs1,2; h3b; hs4 and three enhancers in 
the human: hs3a; hs1,2; hs4. In humans the hs1,2 enhancer has an invariant sequence (IS) 
containing a DRE, NF-κB, NF1 and AP-1 binding site.  Also, the enhancer has an 
AP1.ETS and Oct site located 5’ to the IS.  The human hs1,2 enhancer is sensitive to 
TCDD-induced modulation but in contrast to the mouse hs1,2 and 3’IgH RR, TCDD 
activates the human hs1,2 enhancer.  The current study demonstrates the complexity of 
how TCDD differentially induces modulation between mouse and human and what role 
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I.   INTRODUCTION 
 
 
2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin (TCDD) 
 Dioxins are composed of a polyhalogenated aromatic hydrocarbon and share 
similar biological mechanisms of action.  Based on their hydrophobic properties, 
resistance towards metabolism and long half-life, dioxins tend to bioaccumulate and 
persist as environmental contaminants (Van den Berg et al., 1998).  2,3,7,8-
tetrachlorodibenzo-p-dioxin, also known as TCDD, is the prototypical dioxin (Fig. 1).  
Much research has been dedicated to TCDD, because of its extreme potency as a toxin 













 TCDD is not intentionally produced, except on small scale for research purposes.  
Rather, it is synthesized from chemical reactions or incomplete combustion processes 
involving the presence of chlorine (paper bleaching, metal production, waste incineration, 
fossil fuel and wood combustion, volcanic activity) (ATSDR, 1998).  In the 1960s and 
1970s TCDD contaminated chlorophenoxy herbicides, such as 2,4,5-
trichlorophenoxyacetic acid. This acid was a component of Agent Orange, a defoliant 
used during the Vietnam War (Schecter et al., 2006).  Additionally, industrial accidents 
or environmental application of substances contaminated with TCDD led to evacuations 
of areas around Love Canal in Niagara Falls, New York, Times Beach, Missouri, and 
Seveso, Italy (Friedman et al., 1999; Reggiano, 1979).  More recently, a large number of 
pig and poultry farms in Europe were closed after dioxin contamination was discovered 
in the animal feed.  
 TCDD exposure occurs by ingestion, inhalation or dermal contact when it is 
incorporated into food, water, dust, smoke or air (Mandal, 2005).  Toxic responses to 
TCDD are broad and depend upon many factors, like exposure dose, duration of exposure 
and type of species.  In vivo studies have correlated TCDD to a multitude of 
pathophysiological abnormalities related to brain function, reproduction, hormone 
signaling and immunity (Mandal, 2005).  Moreover, TCDD has been shown to promote 
tumor growth and is classified as a human carcinogen (IARC, 1997).  In all mammalian 
species tested, lethal doses of TCDD lead to excessive loss in body weight preceding 
death (wasting syndrome) (IARC, 1997).  Also, short-term exposure to high levels of 
TCDD in humans can disturb liver function and cause chloracne, a severe acne-like 
condition (Marinkovic et al., 2010).  The mechanism involved in much of TCDD’s 
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toxicity is yet to be determined, but many of its toxic effects are thought to be mediated 
via the aryl hydrocarbon receptor (AhR) signaling pathway.   
 
Aryl Hydrocarbon Receptor Signaling 
 The aryl hydrocarbon receptor (AhR) is a constitutively expressed transcription 
factor belonging to the basic-helix-loop-helix/Per-ARNT-Sim family.  In its inactivated 
state, the AhR is found in the cytosol coupled with several proteins: two heat-shock 
protein 90 molecules, p23, and XAP2.  To date, a variety of chemicals, pharmaceuticals, 
and dietary constituents have been identified as AhR ligands, which can be categorized as 
either man-made or natural in origin (e.g. aromatic hyrdrocarbons, omeprazole, 
flavonoids) (Abel and Haarmann-Steeman, 2010).  When AhR binds a ligand, such as 
TCDD, it undergoes a conformational change and dissociates from the cytosolic proteins.  
The AhR then translocates into the nucleus to form a complex with the aryl hydrocarbon 
receptor nuclear translocator (ARNT).  The TCDD/AhR/ARNT complex binds a dioxin 
responsive element (DRE; 5’-TNGCGTG-3’) within the promoter or enhancer regions of 
sensitive genes and consequently alters gene expression (Fig. 2).  When the AhR ligand is 
no longer present, receptor signaling is seemingly terminated by either nuclear export of 
the receptor, followed by ubiquitination and proteosomal degradation or negative 
feedback-inhibition by the AhR repressor, an inhibitor that binds DREs leading to 
transcriptional repression (Abel and Haarmann-Steeman, 2010). 
 The AhR plays an important role in xenobiotic metabolism and therefore the 
upregulation of a number of drug metabolizing enzymes.  Induction of CYP1A1, a 
member of the cytochrome P450 superfamily of enzymes, is one of the most well-
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characterized gene responses targeted by AhR activation (Fig.2).  CYP1A1 is involved in 
the biotransformation of substrates in phase I reactions and is highly induced by TCDD 
(Whitlock, 1999).  In addition to drug metabolism, many studies have shown that the 
AhR possesses a multitude of diverse functions and capabilities.  A ligand-activated AhR 
is directly involved in cross-talk pathways with androgen and estrogen receptor signaling 
by co-regulating transcription (Ohtake et al., 2008).  Also, UVB irradiation of human 
skin can induce metabolites that activate the AhR (Jux et al., 2010).  The AhR can further 
crosstalk by physically interacting with NF-κB and SP1 and/or altering Nrf2 signaling as 




















   
Figure 2. Aryl hydrocarbon receptor signaling pathway.  TCDD binds to the AhR and 
cytoplasmic proteins dissociate.  TCDD/AhR translocate to the nucleus and bind ARNT.  











The Immune System  
 The immune system is comprised of a variety of cells and mechanisms that work 
to clear the body of foreign antigens like bacteria, viruses, fungi, and/or parasites.  There 
are two arms to immunity: innate and adaptive.  Innate immunity provides an immediate, 
non-specific response towards pathogens and acts as the first line of defense (Medzhitov 
& Janeway, 2000).  Physical barriers, mucosal surfaces and gut flora all resist infection.  
Additionally, phagocytes (macrophages, dendritic cells and neutrophils) recognize 
pathogen-associated molecular patterns and release inflammatory mediators.  Adaptive 
immunity is subsequently activated by the innate system and eliminates specific antigens 
by mounting a strong, highly-specific cellular response (Medzhitov & Janeway, 2000).  
Ultimately, immunological memory of an antigen is retained so that a faster, more robust 
immune response can be achieved upon future exposure to the same antigen.  In adaptive 
immunity there is cell-mediated immunity that is dominated by T cells and humoral 
immunity that is dominated by B cells.  Naïve CD4
+
 TH cells recognize specific epitopes 
bound to major histocompatibility complex (MHC) II molecules found only on the 
surface of an antigen-presenting cell (B cells, dendritic cells, macrophages).  When 
activated, these cells proliferate and differentiate into effector, memory or regulatory TH 
cells and effector TH cells will further differentiate into various subtypes.  Alternatively, 
CD8
+
 cytotoxic T cells respond to an epitope presented by MHC class I molecules, which 
are present on nearly every cell of the body.  MHC II molecules present antigenic 
peptides from pathogens of extracellular origin (e.g. bacteria) whereas MHC I molecules 
present fragments from pathogens of intracellular origin (e.g. viruses).  Both cell-
7 
 
mediated and humoral immunity are interrelated and typically antigen-activated helper T 
cells are needed to effectively activate B cells (Cerutti, 2011). 
 
B Cells 
 When a B cell is activated it eventually undergoes proliferation and differentiation 
into a plasma cell. Antibodies, the soluble form of immunoglobulin (Ig), are then secreted 
from the plasma cell to mark pathogens for destruction or elimination in an effort to 
reduce infection.  There are five main isotypes of Ig (IgM, IgA, IgD, IgG, IgE) and each 
consists of two identical heavy chains and two identical smaller, light chains linked 
together by disulfide bonds (Fig. 3) (Woof & Burton, 2004).  Both the heavy and light 
chain is composed of a variable region that forms the antigen binding site as well as a 
constant region, which is less diverse in its amino acid sequence (Fig. 3).  Ig molecules 
are defined based on differences between the constant region of their heavy chains (CH) 
and each class has distinct effector functions, because of this difference (Woof & Burton, 
2004).  IgM, IgD, IgG, IgE, and IgA are encoded by their respective CH: Cµ, Cδ, Cγ, Cε, 
Cα (Fig. 4).  There are two isotypes for the light chain: lambda and kappa, but no 
functional differences have been found between the two.  Gene segments that encode the 
variable region of the light chain are called variable (V) and joining (J) gene segments.  
The heavy chain variable region includes diversity (D) gene segments as an additional set 














Figure 3. Immunoglobulin (Ig) structure.  Secreted Ig (antibody) is composed of a 
















 Diversity of the antigen binding site is increased by the random combination of 
the gene segments through a process termed, somatic recombination.  During B cell 
development gene segments are cut and spliced so that a V and J gene segment is selected 
and joined for the light chain variable region and likewise a V, D and J segment for the 
heavy chain variable region.  Following successful rearrangement of the light chain and 
heavy chain, an immature B cell will express surface IgM to ensure that there is no 
reaction to self-antigen.  The B cells that pass this test become mature B cells and use 
alternative mRNA splicing to simultaneously produce membrane-bound IgM and IgD.  
Before a B cell differentiates and proliferates in response to an antigen it must be 
activated either with or without T-cell help.  In T-cell dependent activation a T cell 
recognizes an antigen that it is specific for and clonally expands and differentiates into 
effector cells.  This same antigen delivers the first signal to a B cell when it binds the B-
cell receptor (BCR), which is composed of a membrane-bound Ig complexed with Igα 
and Igβ chains.  The second signal is delivered to the B cell when a helper T-cell 
activated by the same antigen recognizes a peptide fragment of the antigen bound to the 
major histocompatibility complex (MHC) class II molecule on the B-cell surface.  These 
two signals together are needed to drive B-cell proliferation and differentiation into 
plasma cells.  In contrast, certain antigens can activate B cells independent of T-cell help.  
One such example is lipopolysaccharide (LPS), an outer membrane component of gram-
negative bacteria.  In addition to binding an LPS-specific BCR, LPS binds the 
CD14/TLR4/MD2 receptor complex, which produces activating signals for inflammatory 
cytokines.  Whether or not T cells are involved, antibody production may proceed once 
the B cell is activated.   
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  IgM is the first antibody produced, but isotype switching can take place to 
change which Ig class is produced by recombining the rearranged V-region DNA with a 
different heavy-chain C gene.  Highly repetitive sequences, called switch regions, 
mediate recombination whereby the switch region that flanks the µ gene interacts with 
the switch region flanking one of the other C genes (Fig. 4).  This interaction allows for 
excision of the previous C gene as a circular DNA molecule bringing the V region and 
new C gene together.  Essentially, antigen specificity can be preserved while the 
functional role of the Ig can be altered.  Somatic hypermutation can also take place, 
which involves point mutations to the rearranged V-region DNA.  Ig with differing 
affinities are produced that allow for its receptor to possess an enhanced ability to bind a 
specific foreign antigen.   
 In the end, an activated B cell develops into a plasma cell or a long-lived memory 
B cell.  The Ig secreted from a plasma cell helps clear the pathogen from the body 
through various ways.  Antibodies can directly bind and neutralize a pathogen or toxin so 
that it cannot interact with human cells.  Also, antibodies can coat pathogens, referred to 
as opsonization, to improve the effectiveness of ingestion by phagocytes.  Alternatively, a 
memory B cell will persist long-term and retain the surface Ig specific for the foreign 
antigen.  When exposed to the same antigen in the future, a quicker immune response can 
be achieved from the memory B cell, because the time required to get a high affinity, 







 The immune system is an early and sensitive target to TCDD-induced toxicity.  
Rodents display a variety of innate and acquired immune-related disturbances following 
acute and chronic exposure to low levels of TCDD (Holsapple et al., 1991; Vos, 1997).  
Examples of responses to TCDD in rodents include immune-cell dysfunction, thymic 
atrophy, susceptibility to infectious diseases and prevention of transplant rejection 
(Luster, 1987; Kerkvliet, 2002).  Although the exact molecular mechanisms responsible 
for the immunosuppressive effects of TCDD have not been clearly established, it is 
believed the AhR plays a vital role.  One study, for example, showed AhR-deficient mice 
were able to mount normal immune responses when exposed to TCDD and challenged 
with different antigens (allogeneic P815 tumor cells, sheep red blood cells) 
(Vorderstrasse et al., 2001).  It seems absence of the AhR does not affect immune system 
function, but the receptor is somehow necessary for immune-related effects of TCDD. 
 
 
TCDD-induced B Cell Dysregulation 
 TCDD affects B cell maturation, activation, differentiation and to a lesser extent 
proliferation (Sulentic and Kaminski, 2011).  Cell separation/reconstitution studies of 
splenocytes determined that B cells are a direct, cellular target of TCDD-induced 
antibody suppression (Holsapple et al., 1986; Dooley and Holsapple, 1988).  TCDD-
cultured B cells activated by lipopolysaccharide (LPS) (T-independent), dinitrophenyl (T-
independent) or sheep red blood cells (T-dependent) provided evidence that inhibition of 
antibody production can occur without T-helper function (Holsapple et al., 1986; Dooley 
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and Holsapple, 1988).  Mitogenic activation increases AhR expression and therefore may 
increase a B cell’s responsiveness to TCDD (Allan and Sherr, 2010).  When activated by 
LPS, mouse B cells (CH12.LX) and purified splenic B cells induce AhR expression 
(Marcus, 1998; Sulentic, 1998).  In LPS-stimulated CH12.LX cells IgM secretion is 
decreased when treated with TCDD while AhR-deficient mouse B cells (BCL-1) did not 
demonstrate an inhibition of IgM secretion when activated by LPS (Sulentic, 1998).  This 
result indicates that antibody production is potentially inhibited by TCDD through an 
AhR-dependent pathway (Sulentic, 1998).  AhR
-/-
 mice mount normal immune responses 
when treated with sheep red blood cells or allogeneic tumor cells and when treated with 
TCDD these responses are not suppressed (Vorderstrasse et al., 2001).  This demonstrates 
that the AhR is not required for normal immune function, but is necessary for TCDD-
induced immune suppression (Vorderstrasse et al., 2001).   
 
 
The Immunoglobulin Heavy Chain Gene Locus 
 The immunoglobulin heavy chain (IgH) gene locus is comprised of the variable 
heavy chain promoter (VH), VDJ region, Eµ intronic enhancer, heavy chain constant 
regions (CH) with germline promoters and the 3’ immunoglobulin heavy chain regulatory 
region (3’IgH RR) (Fig. 4).  There is one 3’IgH RR present in mouse while there are two 
3’IgH RRs present in human-likely the result of an evolutionary duplication event (Mills 
et al., 1997) (Fig. 4).  3’ to the α1 and α2 heavy chain constant regions are the α1 3’IgH 
RR and α2 3’IgH RR, respectively.  The 3’IgH RR plays an important role in modulating 
transcription of the IgH gene, class switch recombination and somatic hypermutation 
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(Cogne et al., 1994; Dunnick et al., 2005; Dunnick et al., 2009).  Splenocytes from 3’ IgH 
RR-deficient mice show a decrease in µ IgH transcripts, defective class switch 
recombination and Ig secretion (Vincent-Fabert et al., 2010).   TCDD along with 
other AhR ligands of dietary, pharmaceutical, environmental and industrial origin inhibit 
transcriptional activity of the 3’IgH RR in LPS-stimulated CH12.LX cells (Sulentic et al., 
2004a; Henseler, 2009).  Additionally, several lymphomas have been correlated with 
chromosomal translocations between the 3’IgH RR and oncogenes.  In Burkitt’s 
lymphoma, translocation of the 3’IgH RR with the cellular oncogene MYC induces 
deregulated gene expression (Yan et al., 2007).  Furthermore, most follicular lymphomas 
contain a chromosomal translocation between the bcl-2 gene and 3’IgH RR that also 
deregulates gene expression and increases resistance to cell death (Heckman et al., 2003).   
 There are four enhancers in the mouse 3’IgH RR (hs3a; hs1,2; hs3b; hs4) and 
three enhancers in the human 3’IgH RR (hs3a; hs1,2; hs4) that display DNase I 
hypersensitivity (Madisen and Groudine, 1994; Chauveau and Cogne, 1996; Mills et al., 
1997) (Fig. 4).  Enhancers of the murine 3’IgH RR display strong synergistic activity 
when in combination versus being independent of one another and individual enhancers 
show different profiles in transcriptional activity depending on the B cell stage (Madisen 
and Groudine, 1994; Saleque et al., 1997; Chauveau, 1998).  The hs4 is active throughout 
B cell development, the hs1,2 is most active in mature B cells and plasma cells and the 
hs3 enhancers have slight activity in activated B cells (Madisen and Groudine, 1994; 
Saleque et al., 1997; Chauveau, 1998).  As a whole, the 3’IgH RR shows less activity in 
pre-B cells compared to surface Ig
+











Figure 4. Immunoglobulin heavy chain (IgH) gene locus.  VH, variable heavy chain 
promoter; Eμ, intronic or μ enhancer; open rectangles, switch regions upstream of heavy 










 Past research shows that mouse 3’IgH RR transcriptional activity in LPS-
stimulated CH12.LX cells is inhibited by TCDD (Sulentic et al., 2004a).  This effect 
parallels TCDD-induced inhibition of µ gene expression and IgM production (Sulentic et 
al., 2000).  The hs4 and hs1,2 enhancers each contain a DRE-like site that demonstrates 
TCDD-inducible binding of AhR/ARNT by EMSA-Western analysis (Sulentic et al., 
2000).  Altered binding to these enhancers supports at least a partial role of DRE-
dependent regulation; however, the AhR is known to interact directly and indirectly with 
a number of different transcription factors such as, AP-1, NF-κB, and SP1 (Suh et al., 
2002; Tian et al., 1999; Kobayashi et al., 1996).  Even though a link between the AhR 
and Oct remains unclear, a high frequency of Oct sites were found in AhR-responsive 
genes using a genetic algorithm thus suggesting a potential role for the transcription 
factor in mediating a response to TCDD (Kel et al., 2004).  Additionally, Oct coordinates 
with NF-κB as a repressor of mouse hs1,2 activity in plasma cells and like NF-κB could 
therefore be modulated by TCDD or the AhR (Michaelson et al, 1996).   
 To determine which enhancer(s) may be responsible for mediating TCDD-
induced inhibition of 3’IgH RR activity, each enhancer was evaluated in isolation.  
Transient transfections of LPS-stimulated CH12.LX cells with a reporter plasmid 
containing the hs4 enhancer resulted in increased activity by TCDD (Sulentic et al., 
2004b).  EMSA analysis indicated AhR/ARNT binding to a region of the hs4 enhancer 
containing a DRE and overalapping NF-κB motif, which could explain how TCDD is 
mediating the enhancer’s activity (Sulentic et al., 2004b).  This outcome is opposite in 
comparison to TCDD’s effects on the overall mouse 3’IgH RR so the hs4 enhancer may 
have a distinct or unrelated function.  Since the mouse hs4 enhancer has the most activity 
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of the four enhancers in pre-B cells, it may have greater influence on early B-cell 
development and VDJ recombination (Chauveau et al, 1998).  One study indicates that 
deletion of the hs4 enhancer does not affect in vitro class switch recombination or Ig 
secretion in response to cytokine or LPS stimulation (Vincent-Fabert et al., 2009).  When 
the mouse hs1,2 enhancer was evaluated in CH12.LX cells similarly to the hs4 enhancer, 
TCDD inhibited transcriptional activity of the enhancer (Fernando et al., 2012).  The 
effects on the hs1,2 enhancer mirrors the suppression of LPS-induced 3’IgH RR activity 
by TCDD making it possible that the hs1,2 enhancer plays an important role in mediating 
transcriptional inhibition of the 3’IgH RR. 
 
The hs1,2 Enhancer 
 While much effort has focused on studying TCDD-induced responses of the 
mouse 3’IgH RR and its enhancers, recent efforts have turned towards human.  Unlike 
the mouse hs1,2 enhancer, the human hs1,2 enhancer is activated by TCDD in LPS-
stimulated CH12.LX cells (Fernando et al., 2012).  Activation of the human hs1,2 
enhancer is similarly demonstrated in a human B-cell line (IM-9) (Fernando et al., 2012).  
The explanation to this interesting dichotomy may be found in the DNA sequences.  
While the core region of the mouse and human hs1,2 enhancers is about 90% similar, 
there are some notable differences (Mills et al., 1997).  The mouse hs1,2 enhancer 
contains two binding sites for Pax5: one low-affinity and one high-affinity (Singh and 
Birshtein, 1993) (Fig. 5).  Pax5, also known as B cell-specific activator protein (BSAP), 
is an important transcriptional regulator involved in determining B cell lineage identity 
and function.  The Pax 5 transcription factor is critical for progenitors to commit to the B-
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cell pathway in early stages while its eventual downregulation permits terminal plasma 
cell differentiation (Cobaleda et al., 2007).  In LPS-stimulated CH12.LX cells Pax5 levels 
decrease, but this down-regulation is inhibited by the presence of TCDD co-treatment 
(Yoo et al., 2004; Schneider et al., 2008).  Deregulation of Pax5 and three of its 
downstream targets (IgH, Igκ, IgJ) imply a role for the transcription factor in TCDD-
mediated impairment of B cell differentiation and Ig expression (Schneider et al., 2009). 
 The human α1 hs1,2 enhancer has a polymorphic region that is absent in the 
mouse hs1,2 enhancer.  The polymorphism consists of an invariant sequence (IS) of 
approximately 55 bp, which can exist one (α1A), two (α1B), three (α1C) or four (α1D) times 
and may alter transcriptional activity (Denizot et al., 2001) (Fig. 5).  Within the IS are 
several binding sites for transcription factors (AP-1, NF1, NF-κB) and also a DRE core-
motif analogous to the functional DRE found in the mouse hs1,2 enhancer (Chen and 
Birshtein, 1997; Denizot et al., 2001; Giambra et al., 2005; Fernando et al., 2012) (Fig. 
5).  This polymorphic region has drawn particular interest, because of its association with 
a number of diseases involving Ig secretion: celiac disease, IgA nephropathy, and 
cutaneous immune-related disorders (Aupetit et al., 2000; Frezza et al., 2004; Cianci et 
al., 2008).  Of the four alleles α1B correlates with increased prevalence or severity of 
these diseases (Aupetit et al., 2000; Frezza et al., 2004; Cianci et al., 2008).  However, 
there were few observed genomes containing the α1C and α1D so their importance should 
not be dismissed (Aupetit et al., 2000; Frezza et al., 2004; Cianci et al., 2008).   It is 
possible that increased transcriptional strength from redundant binding sites affects 
outcomes to correlated diseases. Furthermore, frequency of the α1A, α1B or α1C alleles is 
distributed differently among various population groups indicating the polymorphism 
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may be considered a reliable anthropogenetic marker (Giambra et al., 2006).  African 
populations have the highest frequency of the α1C allele while Asian and European 













































































Significance and Objective 
 
 Previous studies showed inhibition of the mouse hs1,2 enhancer by TCDD 
whereas the human hs1,2 enhancer is activated (Fernando et al., 2012).  It is reasonable 
that these diverging results may be due to differences in the DNA sequence.  As such, it 
is hypothesized that specific transcription factor binding sites of the mouse hs1,2 
enhancer and the human polymorphic hs1,2 enhancer differentially modulate TCDD-
induced activity.  Objective one was to evaluate the transcriptional activity of the Pax5 
binding site that is present in the mouse hs1,2 enhancer yet absent in the human.  Having 
two Pax5 binding sites in the mouse hs1,2 enhancer and none in the human hs1,2 
enhancer may explain why TCDD inhibits the enhancer’s activity in the mouse yet 
activates it in the human.  Objective two was to determine what role the AhR plays in 
TCDD-inducibility of human hs1,2 enhancer activity.    Since the human hs1,2 enhancer 
contains binding sites that are directly or indirectly effected by TCDD or the AhR, it is 
important to establish what involvement the AhR has in enhancer modulation.  Objective 
three was to evaluate the role of specific transcription factors in the human polymorphic 
hs1,2 enhancer.  The IS is especially interesting, because it is associated with several 
immune-related diseases (e.g. celiac disease, IgA nephropathy, and cutaneous immune-
related disorders) and contains transcription factor binding motifs that have been shown 
to interact with the AhR or be modulated by TCDD.   
 The current study has significant implications for several reasons.  First of all, it 
exemplifies the complexity of translating mouse studies to human risk assessment, 
because there are sequence differences in the DNA.  Some transcription factor binding 
sites are contained within both the mouse and human hs1,2 enhancer (AP-1/Ets, Oct, 
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DRE, NF-κB) while other binding motifs are only in the mouse (NF-αP, Pax5) or the 
human (Sp1, NF1, AP-1) (Fig. 5).  Also, this study will further elucidate the mechanism 
involved in TCDD-induced modulation of the hs1,2 enhancer. Evaluating the 
transcriptional activity of specific binding motifs will help clarify the pathway.  Finally, 
researching the 3’IgH RR and hs1,2 enhancer is important, because they are sensitive to 
chemical-induced modulation and associated with a number of lymphomas and Ig-
secreting diseases.  Understanding how this region is governed could provide insight to 
the etiology of certain disease states and how they could be altered along with how these 


































II. MATERIALS AND METHODS 
 
 
Chemicals and Reagents 
TCDD purchased from AccuStandard, Inc. (New Haven, CT) comes dissolved in 100% 
DMSO and the certificate of analysis reports 99.1% purity.  The AhR antagonist 2-
methyl-2H-pyrazole-3-carboxylic acid-(2-methyl-4-o-tolyl-azo-phenyl)-amide (CH-
223191), previously characterized by Kim et al., (2006) was purchased from Calbiochem 
(Carlsbad, CA) and dissolved in 100% DMSO. LPS from Escherichia coli and DMSO 
were purchased from Sigma Alrich (St. Louis, MO).  The LPS was dissolved in 1x 
sterile-filtered PBS.   
 
Cell Line Model 
The CH12.LX mouse B cell line, compliments of Dr. Geoffrey Haughton (University of 
North Carolina, Chapel Hill, NC), is derived from the murine CH12 B-cell lymphoma 








) mouse.  The CH12.LX cell was characterized by 
Bishop and Haughton (1986) and has been used extensively in immunological and 
toxicological research.  There is high AhR expression and a functional AhR signaling 
pathway as well as inhibition of LPS-induced Ig expression by TCDD (Sulentic et al., 
1998, 2000).  For these reasons using the CH12.LX cell line for dioxin studies is useful 





Cell Culture Conditions 
 Cells were kept at 37°C in a 5% CO2 atmosphere and grown in complete media.  
The complete media consisted of RPMI-1640 (Mediatech, Herndon, VA) enhanced with 
2 mM L-glutamine, 10% bovine calf serum (Hyclone, Logan, UT), 13.5 mM HEPES, 0.1 
mM nonessential amino acids, 1.0 mM sodium pyruvate, 100 units/ml penicillin, 100 
µg/ml streptomycin, 50 µM β-mercaptoethanol and 23.8 mM sodium bicarbonate. 
 
Reporter Plasmid Constructs 
 The human polymorphic plasmids utilize the pGL3 basic luciferase reporter 
construct (Promega, Madison, WI) containing ampicillin resistance and the luciferase 
gene.  The enhancerless variable heavy chain promoter (VH) plasmid and the α1A, α1B and 
α1C plasmids were a generous gift from Dr. Michel Cogné (Université de Limoges, 
France) (Fig. 6). Of the plasmids that contain the human hs1,2 enhancer there is an 
invariant sequence (IS) that may be present one (α1A), two (α1B) or three (α1C)  times (Fig. 
6).  The IS can also be present four (α1D) times, but was not studied because of low 
prevalence.  Each IS is approximately 55 bp in length and contains several transcription 
factor binding sites (AP-1, NF1, NF-κB, DRE), as previously mentioned (Chen and 
Birshtein, 1997; Denizot et al., 2001; Giambra et al., 2005; Fernando et al., 2012).  The 
DRE and AP-1 binding sites found in the third IS of the α1C are not conserved.  However, 














Figure 6. Human polymorphic hs1,2 reporter plasmid constructs.  The asterick (*) 



































 The QuikChange Lightning Site-Directed Mutagenesis Kit (Stratagene, La Jolla, 
CA) consists of a four-step process involving plasmid preparation, temperature cycling, 
digestion, and finally transformation.  Each mutation reaction used 5 µl of 10X reaction 
buffer, 100 ng of parental template, 125 ng each of forward and reverse mutation primers, 
1 µl of dNTP mix, 1.5 µl of QuikSolution reagent and ddH20 for a final volume of 50 µl.  
1 µl of QuikChange Lightning Enyzme was added before thermal cycling.  PCR 
conditions used are as follows: 95ºC for 2 min followed by 18 cycles at 95ºC for 20 s, 
60ºC for 10 s, 68ºC for 2.75 min (30 sec/kb of plasmid length), then 68ºC for 5 min.  
After the PCR reaction, the parental plasmid was digested by incubating the PCR product 
with Dpn I (2 μL/50 μL reaction) for 5 min at 37ºC.  2 µl of Dpn I-treated DNA was used 
to transform 45 µl of XL10-Gold® ultracompetent cells.  Plasmid DNA was isolated 
from transformed colonies and sequenced to ensure quality and accuracy of the mutations 
(Retrogen, Inc., San Diego, CA).  For the α1A plasmid one high-affinity Pax5 site was 
added and the AP-1, NFκB, DRE, Oct, AP1.ETS, 5’ SP1 and 3’ SP1 sites were mutated: 
termed α1A+Pax5, α1AAP1mut, α1ANFκBmut, α1ADREmut, α1AOctmut,  α1AAP1.ETSmut, 
α1ASP1.1mut and α1ASP1.2mut, respectively (Table 1).  Additionally, the invariant 
sequence (IS) was deleted from the α1A (α1AISdel) and mutants containing the IS deleted 
plus the Oct site mutated (α1AISdelOctmut) and the DRE site plus NF-κB mutated 
(α1ADRE.NFκBmut) were also generated (Table 1).   In the α1B plasmid the first IS was 
deleted (α1BIS1del) or the AP-1 (α1BAP1.1mut), NF-κB (α1BNFκB.1mut), DRE 
(α1BDRE.1mut) sites were individually mutated from the first IS (Table 2).  Lastly, for 
the α1C plasmid the third IS was deleted (α1CIS3del) and the NF-κB site in the first IS was 
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mutated (α1CNFκB.1mut) (Table 2).  A sequenced human sample containing the α1C  
hs1,2 enhancer  showed consensus-matching DRE and AP-1 sites in the third IS so both 
sites were mutated and restored back to their respective consensus sequences 
(α1CClinical) (Table 2).  Mutations of transcription factor binding sites were determined 
based off of enzyme mobility shift assay data and TFSEARCH, an online transcription 
factor profile database (Grant et al., 1995; Heinemeyer et al., 1998; Yao and Denison, 


























F: 5’- GTGGTCCCAGTGTCAGCCCTGGGGTGTTGAGCCACCCATCCTTGC CCTAACCCAAGTGGGCCT -3’ 
 







F: 5'-TGTCCCCGAATCTGGAGGCCCTTAGATGCCTGGCCACGCTGGGGGAG-3                                                    
                                                    CCGGACTCGGTCGG 









                                                           CGCCCACAGGGGCTTA 
                                                           GCGGGTGTCCCCG AAT 
R: 3'-GGACAGGACCCCCTCCCCCGTCAAGAAGATGTTAGACCTCCGGACTCGGTC-5' 






                                         ACCGGTGCGACCC 









                                                                          TGGTAAACGTACACG 
                                                                          ACCATT T GCAT G TGC                                       
R: 3'-GTACAAAAGCCACACCTTGTTTGTTGGCTGAATCCCACGGGACTCCCGGTTCAGACGGGTCT-5' 





                               CCCCGCCC……..CGACCCT 









                                                                     GGTCT T ACTCAGTGA 
                                                                      CCAGAATGAGTCACT 
R: 3'-CACGGGACTCCCGGTTCAGACGGGGATCAACCGGGGAGTTCCTCTTTGTCTAGTCTCGG-5' 
 




                                                   C T  CCCCCGCCCAC 








                                                            CTCCCCCGCCCT 















Serial mutagenesis performed using primer sets from α1AISdel and α1AOctmut 
 
 
Table 1. α1A site-directed mutagenesis primers.  Bolded sequence denotes addition or 



























Table 2. α1B and α1C site-directed mutagenesis primers.  Bolded sequence denotes 












                                                          CGACCGAGTC 








                                                          GCCCCTGTGGGG 








                                                   GTCGCACCG 




α 1BIS1del  
 
 
F: 5'- GCACGATTCTCCC……………..………….CCCCACCACAGCG--3' 
                                     GGGCGGG…………..GGGGGGGT 









                                                      GCCCACAGGGGC 








                             GGTGGGCCAC………. GCACACA 








                                      CCCGGG…GCGCGA 






 1.0 x 10
7 
cells were pelleted by centrifugation at 300 x g for 5 minutes at 4°C.  
Media was removed and cells were resuspended with 10 µg of plasmid and enough media 
to bring the final volume up to 200 µl.  200 µL (1.0 x 10
7 
cells) was transferred to a 2mm 
electroporation cuvette and electroporated at 250 V, 150 µF, and 75 ohms.  Each plasmid 
was transfected multiple times and cells were pooled and diluted to obtain 2 x 10
5
 
cells/mL.  Transfected cells were cultured in the absence of any additional treatment 
(naïve, NA) or treated with 0.01% DMSO (vehicle control-0 nM TCDD) or TCDD (0.01 
nM, 0.1 nM, 1.0 nM, 10 nM) in the absence or presence of LPS (1.0 or 0.1 µg/ml) 
stimulation.  Different LPS concentrations were used, because different lots of LPS 
varied in potency.  Cells were aliquoted into 12-well plates (n=3) and incubated at 37°C 
in 5% CO2 for 24 hours. In AhR antagonist studies, cells were pre-treated with the 
antagonist (15µM) for 1 hour prior to additional treatments. 
 
Luciferase Assay System 
 After the 24 hour incubation period, cell culture plates were centrifuged at 1800 x 
g for 5 minutes at 4°C.  Supernatant was removed and cells were lysed with 1x lysis 
buffer (Promega, Madison, WI) and immediately frozen at -80°C for no less than 1 hour.  
To quantify gene expression the Luciferase Assay System (Promega, Madison, WI) was 
used to measure luciferase enzyme activity.  Samples were thawed to room temperature 
and centrifuged at 20,000 x g for 5 minutes at 4°C. 20 µl of sample lysate was mixed 
with 100 µl of luciferase substrate reagent and a single-tube luminometer (Berthold 
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Detection Systems, Oak Ridge, TN) reported light measurements as relative light units 
(RLUs) following each reaction.   
 
Transfection Efficiency 
 An additional group of naïve cells were seeded for each transfected plasmid to 
determine transfection efficiency.  TCDD or LPS treatments do not affect transfection 
efficiency (data not shown).  DNA was isolated through a genomic DNA miniprep kit 
(Sigma Aldrich, St. Louis, MO) at 4 hrs post-transfection and diluted 10-fold. Real-time 
polymerase chain reaction (RT-PCR) was performed by using absolute quantification.  In 
a 96-well plate each sample well contained 23 µl of the reaction master mix [12.5 µl 2x 
SYBR Green (Applied Biosystems, Warrington, UK), 1 µl 10 pmol/µl forward primer-
pGL3 luciferase, 1 µl 10 pmol/µl reverse primer-pGL3 luciferase, and 8.5 µl purified 
water] and 2 µl of sample DNA.  The forward and reverse primers are 5’-
ACTGGGACGAAGACGAACACTT-3’ and 5’-TCAGAGACTTCAGGCGGTCAA-3’, 
respectively.  Sample PCR data was compared to a standard luciferase reporter plasmid 
with concentrations ranging from 0.1 ng/µl to 1x10
-6 
ng/µl.  Amount of transfected 
plasmid (ng) was calculated by taking the concentration of DNA from the PCR results 
(ng/µl) x the volume of DNA added (2µl) x the fold dilution (10).  Number of plasmids 
per cell was calculated from the equation: [ng of plasmid DNA x number of plasmids/ng] 
÷ total number of cells isolated (previously described in Sulentic et al., 2004).   





Statistical Analyses of Data 
 Comparisons between treatment groups (n=3) of the same reporter plasmid were 
analyzed using a 1-way ANOVA followed by a Dunnett’s Multiple Comparison post test.  
Significant differences in luciferase activity (mean ± SEM) were compared to the 
corresponding vehicle control and represented by “*”, “**”, “***” at p<0.05, p<0.01 and 
p<0.001, respectively.  Differences in TCDD-induced fold change was determined in the 
same manner and denoted by “‡”, “‡‡”, “‡‡‡” at p<0.05, p<0.01 and p<0.001, 
respectively.  Differences in luciferase activity or fold change between reporter plasmids 
were analyzed using a 2-way ANOVA with Bonferroni post test.  Daggers, “†”, “††”, 
“†††”, denote significant differences between different reporter plasmids at p<0.05, 
p<0.01 and p<0.001, respectively.  Multiple, separate experiments (n=3 for each 
treatment group) were used to generate TCDD-induced fold change results (mean ± 
SEM).  Synergism was calculated by normalizing relative light units (RLUs) of plasmids 
to the average NA RLU of the wildtype plasmid (VH or α1A).  RLU data has already 
undergone normalization to transfection efficiency.  The average DMSO vehicle RLU 
was subtracted from treatment RLUs of its respective plasmid enable to compare an 











Insertion of a Pax5 binding site lowers transcriptional activity of the human hs1,2 
enhancer  
 Previous transient transfections of CH12.LX cells show that TCDD inhibits 
transcriptional activity of the mouse hs1,2 enhancer yet activates the human hs1,2 
enhancer (Fernando et al., 2012).  It is possible that these diverging outcomes may be due 
to the presence of two Pax5 binding sites (one high-affinity and one low-affinity) in the 
mouse hs1,2 enhancer and none in the human hs1,2 enhancer.  The B-cell lineage specific 
activator protein (BSAP) that binds Pax5 sites is expressed early in B-cell differentiation, 
but is consequently down-regulated following B-cell activation (e.g. LPS).  TCDD 
treatment inhibits this natural downregulation of BSAP (Yoo et al., 2004; Schneider et 
al., 2008).   
 Using site-directed mutagenesis, one high-affinity Pax5 binding site was added to 
the human α1A plasmid (α1A + Pax5).  Overall transcriptional activity was lowered by the 
Pax5 site and significant differences in luciferase activity were observed between 
plasmids for nearly every unstimulated and LPS-stimulated treatment (Fig. 7A).  Basal 
activity was minimally lowered by insertion of the Pax5 site while LPS-induced activity 
was markedly suppressed (Fig. 7A).  Furthermore, α1A demonstrated synergism from 
LPS/TCDD cotreatment while α1A + Pax5 did not (Fig. 7A).  However, contrary to 
expectation, the Pax5 binding site did not seem to alter TCDD-induced fold-change 
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activation of the human hs1,2 enhancer (Fig. 7B).  Even though TCDD still increased α1A 
transcriptional activity in a concentration-dependent manner that appeared unrelated to 
the Pax5 site overall transcription was still lower for α1A + Pax5 (Fig. 7A and 7B).  
Although these outcomes may dismiss the role Pax5 may have in the inhibition of mouse 
hs1,2 activity by TCDD further consideration should be warranted, because of the 




























Figure 7.  A Pax5 site decreases overall transcriptional activity of the α1A.  CH12.LX 
cells were transiently transfected with α1A or α1A + Pax5 reporter plasmids. Transfected 
cells were either cultured in the absence of any additional treatment (naïve, NA) or 
treated for 24 h with 0.01% DMSO vehicle (0 nM TCDD) or TCDD (0.001-10.0 nM) in 
the absence or presence of LPS (1 µg/ml) stimulation.  A. Luciferase enzyme activity 
(mean ± SEM, n=3) is represented on the y-axis as relative light units normalized to 
transfection efficiency.  C represents the LPS alone control.  B. Fold change is 
represented on the y-axis relative to the respective DMSO vehicle control and was 
generated from averaging the means of independent experiments (n=3 for each treatment 
group within each experiment).  Comparisons between treatment groups were analyzed 
using a 1-way ANOVA followed by a Dunnett’s Multiple Comparison post test. 
Asterisks, “*”, “**”, or “***” denote significance compared to the corresponding vehicle 
set to 1 at p<0.05, p<0.01 or p<0.001, respectively.  Comparisons between reporter 
plasmids were analyzed using a 2-way ANOVA Bonferroni post test.  Daggers, “†”, 
“††”, “†††”, denote significant differences between reporter plasmids for each treatment 
at p<0.05, p<0.01 and p<0.001, respectively.  Vertical line represents significance 
difference between all treatment groups between reporter plasmids at p<0.001.  > denotes 
synergistic activation by LPS and TCDD cotreatment compared to the activation of either 
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TCDD activates the human polymorphic hs1,2 enhancer in an AhR-dependent 
manner 
 The antagonist, CH-223191, was used to test if the AhR is essential for TCDD-
induced activation of the human polymorphic hs1,2 enhancer.  CH12.LX cells were 
transiently transfected with the VH, α1A, α1B or α1C luciferase reporter plasmids then 
treated with the AhR antagonist making the receptor inaccessible and unable to 
translocate to the nucleus.  Transcriptional activity of basal and LPS levels of the VH 
remained low while α1A and α1B had similarly higher activity and α1C demonstrated the 
most activity (Fig. 8A). TCDD expectedly activated the human hs1,2 enhancer when 
containing one, two or three invariant sequences in both unstimulated and LPS-stimulated 
cells (Fig. 8A and 8B ).  Cells treated with both the antagonist and TCDD displayed a 
reversal of enhancer activation thus exemplifying the necessity of the receptor (Fig. 8A 
and 8B).  Also, α1A, α1B and α1C demonstrated synergism from LPS/TCDD cotreatment 
compared to either treatment by itself (Fig. 8A).  The fold change between the human 
polymorphic reporter plasmids were quite similar, which means that the number of 
invariant sequences present may be less important to what degree the human hs1,2 
enhancer is activated by TCDD (Fig. 8B).  In essence, these results indicate that the AhR 
is necessary for TCDD to activate the enhancer, but whether it is directly or indirectly 
involved in the mechanism is yet to be determined.  Either the TCDD/AhR/ARNT 
complex is binding the hs1,2 enhancer or TCDD and/or the AhR is altering binding of 


















Figure 8.  TCDD-induced activation of the human polymorphic enhancer is AhR 
dependent.  CH12.LX cells were transiently transfected with VH, α1A, α1B, or α1C reporter 
constructs.  Transfected cells were either pre-treated for 1 hr with 15 µM AhR antagonist 
(CH-223191), 0.15% DMSO, or media alone then cultured for 24 h in the absence or 
presence of LPS (1.0 µg/mL) stimulation and either media alone, 0.01% DMSO, or 1 nM 
TCDD.  “Control” denotes either unstimulated naive or LPS alone.  A. Luciferase 
enzyme activity (mean ± SEM, n=3) is represented on the y-axis as relative light units 
(RLUs) normalized to transfection efficiency.  B. Fold change is represented on the y-
axis relative to the respective DMSO vehicle control and was generated from averaging 
the means of independent experiments (n=3 for each treatment group within each 
experiment).  Significance was determined by a 1-way ANOVA followed by a Dunnett’s 
Multiple Comparison post test: “*”, “**”, “***”, significance compared to the 
corresponding DMSO vehicle control at p<0.05, p<0.01 and p<0.001, respectively; “‡”, 
“‡‡”, “‡‡‡”, significant difference between TCDD alone and TCDD + AhR antagonist.  
Significance compared to the VH reporter was determined by a 2-way ANOVA with a 
Bonferroni’s post-hoc test: “†” and “†††”, significance at p<0.05 and p<0.001, 
respectively.  > denotes synergistic activation by LPS and TCDD cotreatment compared 

























































Control DMSO TCDD TCDD + AhR antagonist



























































































































Control DMSO TCDD TCDD + AhR antagonist





















Deletion of the invariant sequence lowers overall transcriptional activity of the 
human hs1,2 enhancer 
 As previously mentioned the invariant sequence (IS) contains a number of 
transcription factor binding sites (DRE, AP-1, NF1, NF-κB) and is flanked by SP1 sites 
on both the 5’ and 3’ end (Chen and Birshtein, 1997; Denizot et al., 2001; Giambra et al., 
2005; Fernando et al., 2012).  TCDD and/or the AhR have been shown to affect these 
transcription factors so evaluation of this region may explain how TCDD induces the 
hs1,2 enhancer.  The α1A and α1B plasmids contain one and two IS, respectively.  
Sequencing results of the α1C plasmid indicate the DRE and AP-1 sites of the third IS are 
not entirely conserved, but this is contrary to human sequencing (Denizot et al., 2001; 
Fernando et al., 2012).  To determine how the polymorphism affects transcriptional 
activity and TCDD-induced fold change of the hs1,2 enhancer the IS was deleted from 
the α1A and α1B.  Transient transfection into CH12.LX cells of the deleted IS from the α1A 
(α1AISdel) showed a significant decrease in overall transcriptional activity of the human 
hs1,2 enhancer (Fig. 9A).  Luciferase activity is decreased for both unstimulated and LPS 
stimulated treatments when the IS is deleted, but TCDD-induced fold-change activation 
is still parallel with α1A (Fig. 9A and 9B).  Deleting the first IS from the α1B (α1BIS1del) 
revealed a similar outcome to the α1AISdel by lowering the transcriptional activity for all 
treatment groups (Fig 9A).  Interestingly, the α1BIS1del still displayed more overall 
activity than the α1A (Fig 10A).  Either the additional IS cannot account for all of the 
activity of the enhancer and the other transcription factors found outside the 
polymorphism are involved or the deletion generates a compensating mechanism.  
Furthermore, the α1A, α1AISdel, α1BIS1del and α1B all showed similar profiles in 
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synergistic activation from LPS and TCDD cotreatment (Fig. 9A and 10A).  Again, no 
significant differences in the magnitude of TCDD-induced fold-change activation were 
observed between the α1BIS1del, α1A or α1B, but there is a noticeable decrease in LPS 
stimulated fold-changes of the α1BIS1del when compared to the α1B  (Fig. 10B).  A slight 
decrease in α1AISdel stimulated fold-changes is also seen when compared to the α1A, 
which may suggest that multiple transcription factors both within and outside the IS work 

























































































































































Figure 9.  Deletion of the IS from the α1A reduces overall transcriptional activity.  
CH12.LX cells were transiently transfected with α1A or α1AISdel reporter plasmids. 
Transfected cells were either cultured in the absence of any additional treatment (naïve, 
NA) or treated for 24 h with 0.01% DMSO vehicle (0 nM TCDD) or TCDD (0.001-10.0 
nM) in the absence or presence of LPS (1 µg/ml) stimulation.  C represents the LPS alone 
control.  A. Luciferase enzyme activity (mean ± SEM, n=3) is represented on the y-axis 
as relative light units (RLUs) normalized to transfection efficiency.  B.  Fold change is 
represented on the y-axis relative to the respective DMSO vehicle control and was 
generated from averaging the means of independent experiments (n=3 for each treatment 
group within each experiment). Comparisons between treatment groups of the same 
plasmid were analyzed using a 1-way ANOVA followed by a Dunnett’s Multiple 
Comparison post test.  Asterisks, “*” or “**”, denote significance compared to the 
corresponding vehicle control at p<0.05 or p<0.01, respectively.  Comparisons between 
reporter plasmids were analyzed using a 2-way ANOVA Bonferroni post test.  Daggers, 
“†††”, denote significant differences between reporter plasmids for each treatment at 
p<0.001.  > denotes synergistic activation by LPS and TCDD cotreatment compared to 


















Figure 10.  Deletion of the first IS from the α1B lowers overall transcriptional 
activity of the human hs1,2 enhancer.  CH12.LX cells were transiently transfected with 
α1A, α1BIS1del or α1B reporter plasmids. Transfected cells were either cultured in the 
absence of any additional treatment (naïve, NA) or treated for 24 h with 0.01% DMSO 
vehicle (0 nM TCDD) or TCDD (0.001-10.0 nM) in the absence or presence of LPS (1 
µg/ml) stimulation.  C represents the LPS alone control.  A.  Luciferase enzyme activity 
(mean ± SEM, n=3) is represented on the y-axis as relative light units (RLUs) normalized 
to transfection efficiency.  B.  Fold change is represented on the y-axis relative to the 
respective DMSO vehicle control and was generated from averaging the means of 
independent experiments (n=3 for each treatment group within each experiment). 
Comparisons between treatment groups of the same plasmid were analyzed using a 1-way 
ANOVA followed by a Dunnett’s Multiple Comparison post test.  Asterisks, “*” or “**”, 
denote significance compared to the corresponding vehicle control at p<0.05 or p<0.01, 
respectively.  Comparisons between reporter plasmids were analyzed using a 2-way 
ANOVA Bonferroni post test.  Daggers, “††” or “†††”, denote significant differences 
between reporter plasmids for each treatment at p<0.01 or p<0.001. > denotes synergistic 
activation by LPS and TCDD cotreatment compared to the activation of either treatment 























































































































































Mutation of the invariant sequence AP-1 or NF-κB site increases overall 
transcription of the human hs1,2 enhancer  
 The activator protein-1 (AP-1) binding site (TGGCTCA) and nuclear factor kappa 
B (NF-κB) site (GGGACACCC) are located within the invariant sequence (IS) of the 
human polymorphic hs1,2 enhancer (Denizot, 2001).   It has been shown that AP-1 or 
NF-κB are affected by the AhR or TCDD through cross-talk interactions or altered 
binding and expression (Suh et al., 2002; Tian, 2002).   Evaluation of these sites is 
therefore necessary, because each may be involved in the TCDD-induced activation of 
the human hs1,2 enhancer. 
 A number of studies have reported TCDD-induced influence on AP-1, but 
outcomes vary on whether the transcription factor’s activity increases or decreases.  In 
LPS-activated CH12.LX cells, one study showed that TCDD upregulated AP-1 binding 
within the promoter of B lymphocyte–induced maturation protein-1 (Blimp-1), a critical 
regulator of B-cell differentiation and a negative transcriptional repressor of Pax5 
(Schneider et al., 2009).  In this same study a link was made between TCDD-mediated 
suppression of Blimp-1 through AP-1 binding and Pax5 dysregulation (Schneider et al., 
2009).  Also, other studies conducted in multiple liver cell types showed an increase in 
AP-1 DNA binding activity resulting from genes induced by AhR agonists (Puga et al., 
1992; Ashida et al., 2000).  In opposition Suh and coworkers demonstrated that TCDD 
inhibited DNA binding and transcriptional activity of AP-1 in LPS-activated CH12.LX 
cells (2002).  In the same study TCDD was unable to inhibit AP-1 activity in an AhR-
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deficient murine B cell line, BCL-1 (Suh et al., 2002).  Even though TCDD-induced 
effects on AP-1 differ, it is clear that the transcription factor is targeted.     
 Site-directed mutagenesis was used to mutate the AP-1 site in the α1A reporter 
plasmid (α1AAP1mut), which was then transiently transfected into CH12.LX cells.  The 
α1AAP1mut resulted in significantly higher transcription of the human hs1,2 enhancer in 
both unstimulated and LPS-stimulated CH12.LX cells (Fig. 11A).  Also, synergism was 
similarly exhibited by α1A and α1AAP1mut.  Although differences were not significant, 
averaged TCDD-induced fold-change data from several experiments show a trend for 
greater activation of α1A as compares to α1AAP1mut at higher concentrations of TCDD in 
LPS-stimulated CH12.LX cells (Fig. 11B).  The AP-1 site seems to play an important 
role in the overall transcription of the human hs1,2 enhancer, but may not play a 
dominant role in TCDD-induced modulation. 
 Like the IS AP-1 site, TCDD-induced modulation of the human polymorphic 
hs1,2 enhancer may involve the IS NF-κB site.  NF-κB activity contributes to the 
activation of hs1,2 enhancer at the plasma cell stage (Michaelson et al., 1996). Also, the 
transcription factor has been found to modulate AhR signaling, which may explain how 
TCDD-induced immunotoxicity is mediated (Tian, 2009).  Transcriptional activity of the 
AhR and NF-κB has been shown to be regulated by the same corepressors and 
coactivators, such as Steroid receptor coactivator-1 (SRC-1) and p300/CBP (Tian, 2009).  
Because coregulators are required for both pathways, it is possible that competition for 
binding occurs causing one pathway to be active while the other pathway is suppressed 
(Tian, 2009).   
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 In its evaluation the NF-κB site was mutated from the α1A reporter plasmid 
(α1ANFκBmut).  Transient transfections of CH12.LX cells resulted in significantly higher 
transcriptional activity from mutation of the NF-κB site in both unstimulated and LPS-
stimulated cells (Fig. 12A).  Although the overall transcriptional activity differed 
between mutated and nonmutated plasmids, TCDD-induced activation and synergism still 
occurred in both (Fig. 12A and 12B).  In unstimulated cells mutating the NF-κB site did 
not affect fold-change activation when compared to α1A (Fig. 12B).  However, in LPS-
stimulated cells the mutation appears to show a lesser degree of fold change activation for 
all concentrations of TCDD (Fig. 12B).   
 Overall transcriptional activity is clearly affected by the AP-1 and NF-κB 
mutations. TCDD positively regulates hs1,2 enhancer activity and mutation of these IS 
sites further increases TCDD-induced activity. However, mutations of the AP-1 site and 
NF-κB site each showed slightly lower TCDD-induced fold changes in LPS-stimulated 
CH12.LX cells (Fig. 11B and 12B).  Each site may naturally repress overall hs1,2 
activity, but still assist in TCDD-induced enhancer activation.  It seems likely that several 



















Figure 11.  Mutation of the IS AP-1 site increases overall transcriptional activity 
and slightly decreases TCDD-induced activation of the human polymorphic hs1,2 
enhancer. CH12.LX cells were transiently transfected with α1A or α1AAP1mut reporter 
plasmids. Transfected cells were either cultured in the absence of any additional 
treatment (naïve, NA) or treated for 24 h with 0.01% DMSO vehicle (0 nM TCDD) or 
TCDD (0.01-10.0 nM) in the absence or presence of LPS (0.1 µg/ml) stimulation.  C 
represents the LPS alone control.  A.  Luciferase enzyme activity (mean ± SEM, n=3) is 
represented on the y-axis as relative light units (RLUs) normalized to transfection 
efficiency.  B.  TCDD-induced activation is represented on the y-axis as fold change 
relative to the DMSO vehicle. Results (mean ± SEM) were generated from separate 
experiments (n=3 for each treatment group within each experiment).  Comparisons 
between treatment groups of the same plasmid were analyzed using a 1-way ANOVA 
followed by a Dunnett’s Multiple Comparison post test.  Asterisks, “*”, “**” or “***”, 
denote significance compared to the corresponding vehicle control at p<0.05, p<0.01 or 
p<0.001, respectively.  Comparisons between reporter plasmids were analyzed using a 2-
way ANOVA Bonferroni post test.  Daggers, “††”, “†††”, denote significant differences 
between reporter plasmids for each treatment at p<0.01 and p<0.001, respectively.  > 
denotes synergistic activation by LPS and TCDD cotreatment compared to the activation 



















































































































































Figure 12.  Mutation of the IS NFκB site of the α1A increases overall transcription 
and slightly lowers stimulated TCDD-induced fold change.  CH12.LX cells were 
transiently transfected with α1A or NFκBmutα1A reporter plasmids. Transfected cells were 
either cultured in the absence of any additional treatment (naïve, NA) or treated for 24 h 
with 0.01% DMSO vehicle (0 nM TCDD) or TCDD (0.01-10.0 nM) in the absence or 
presence of LPS (0.1 µg/ml) stimulation.  C represents the LPS alone control.  A.  
Luciferase enzyme activity (mean ± SEM, n=3) is represented on the y-axis as relative 
light units (RLUs) normalized to transfection efficiency.  B.  TCDD-induced activation is 
represented on the y-axis as fold change relative to the DMSO vehicle. Results (mean ± 
SEM) were generated from separate experiments (n=3 for each treatment group within 
each experiment).  Comparisons between treatment groups of the same plasmid were 
analyzed using a 1-way ANOVA followed by a Dunnett’s Multiple Comparison post test.  
Asterisks, “*”, “**” or “***”, denote significance compared to the corresponding vehicle 
control at p<0.05, p<0.01 or p<0.001, respectively.  Comparisons between reporter 
plasmids were analyzed using a 2-way ANOVA Bonferroni post test.  Daggers, “††”, 
“†††”, denote significant differences between reporter plasmids for each treatment at 
p<0.01 and p<0.001, respectively.  > denotes synergistic activation by LPS and TCDD 
cotreatment compared to the activation of either treatment alone.  Results are 







































































































































Mutating the AP1.ETS site decreases overall transcriptional activity of the human 
hs1,2 enhancer 
 The AP1.ETS (TGACTCATTCT) site is located 5’ to the invariant sequence (IS).  
There is a single nucleotide difference between the mouse and human AP1.ETS site, 
which causes the human AP-1 site to match the consensus (Mills et al., 1997). In the 
murine hs1,2 enhancer the AP1.ETS site confers responsiveness to B-cell receptor cross-
linking and has a functional role in 3’IgH RR activity (Grant et al., 1995).  Following 
IgM receptor activation of primary B lymphocytes or BAL-17 cells enhancer activation 
was concurrent with recruitment and binding of nuclear factor of activated B cells 
(NFAB) to the AP1.ETS site (Grant et al., 1995).  Because of its demonstrated role in 
murine enhancer activity, it is necessary to explore what role the AP1.ETS site plays in 
the human hs1,2 enhancer and how TCDD-induced modulation is altered.  Mutation of 
the AP1.ETS site (α1AAP1.ETSmut) within the α1A reporter plasmid followed by transient 
transfection of CH12.LX cells resulted in a markedly lower overall transcriptional 
activity for unstimulated and LPS-stimulated treatments with or without TCDD (Fig. 
13A).  Additionally, α1A demonstrated more synergism than α1AAP1.ETSmut (Fig. 13A).  
Of all the individual transcription factor binding sites evaluated in this study, mutation of 
the AP1.ETS was the only one that decreased luciferase activity.  Again, no significant 
differences in TCDD-induced fold-change were observed between the α1AAP1.ETSmut 
and α1A, but the motif seems to account for much activity of the human hs1,2 enhancer 








































































 Figure 13.  Mutation of the AP1.ETS site decreases overall transcriptional activity 
of the human hs1,2 enhancer.  CH12.LX cells were transiently transfected with α1A or 
α1AAP1.ETSmut reporter plasmids. Transfected cells were either cultured in the absence 
of any additional treatment (naïve, NA) or treated for 24 h with 0.01% DMSO vehicle (0 
nM TCDD) or TCDD (0.01-10.0 nM) in the absence or presence of LPS (0.1 µg/ml) 
stimulation.  C represents the LPS alone control.  A.  Luciferase enzyme activity (mean ± 
SEM, n=3) is represented on the y-axis as relative light units (RLUs) normalized to 
transfection efficiency.  B.  TCDD-induced activation is represented on the y-axis as fold 
change relative to the DMSO vehicle. Results (mean ± SEM) were generated from 
separate experiments (n=3 for each treatment group within each experiment).  
Comparisons between treatment groups of the same plasmid were analyzed using a 1-way 
ANOVA followed by a Dunnett’s Multiple Comparison post test.  Asterisks, “*”, “**” or 
“***”, denote significance compared to the corresponding vehicle control at p<0.05, 
p<0.01 or p<0.001, respectively.  Comparisons between reporter plasmids were analyzed 
using a 2-way ANOVA Bonferroni post test.  Daggers, “†††”, denote significant 
differences between reporter plasmids for each treatment at p<0.001.  > denotes 
synergistic activation by LPS and TCDD cotreatment compared to the activation of either 
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Involvement of Oct and AP1.ETS motifs and the invariant sequence in human hs1,2 
enhancer activity 
 Like the AP1.ETS site the transcription factor, octamer (Oct-ATGCAAAT), is 
located 5’ of the invariant sequence (IS).  Oct contributes to mouse hs1,2 enhancer 
activity and is conserved between mouse and human (Mills et al., 1997).  In B cells Oct 
in collaboration with G-rich, κB-like motifs and BSAP repress transcription of the murine 
hs1,2 enhancer (Singh and Birshtein, 1996).  Even though little is known of TCDD-
induced effects on Oct, its active role in enhancer activity makes it a site of interest.  
Furthermore, the binding motif is frequently present in AhR-sensitive genes (Kel et al., 
2004), which means that it could have a vital role in AhR signaling and TCDD-induced 
modulation.  When Oct was mutated (α1AOctmut) from the α1A plasmid and transiently 
transfected into CH12.LX cells, transcriptional activity increased for unstimulated and 
LPS-stimulated treatments both with and without TCDD (Fig. 14A).  Interestingly, 
mutation of Oct generated a significant increase in unstimulated TCDD-induced fold-
change activation compared to α1A (Fig. 14B).  When the Oct was mutated from the 
α1AISdel (α1AOctmutISdel) there was still more luciferase activity than the α1A wildtype 
and even the α1AOctmut (Fig. 14A).  Also, stimulated TCDD-induced fold changes of the 
α1AOctmutISdel were not as high as the α1A (Fig. 14B).   
 To assess relative differences in transcriptional activity VH, α1A, α1AAP1.ETSmut, 
α1AOctmutISdel, and α1AISdel were transiently transfected into CH12.LX cells.  
Transfecting the α1AAP1.ETSmut and α1AISdel together will indicate the degree of 
transcriptional suppression between one another in comparison to VH and α1A activity.  
The α1AAP1.ETSmut showed luciferase activity only slightly higher than VH levels, but 
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noticeably lower than α1AISdel, which suggests the AP1.ETS site is responsible for more 
enhancer activity than the IS (Fig. 15).  Also, evaluating the α1AOctmutISdel and 
α1AISdel together in this experimental design will address what impact mutating the Oct 
site has in combination with the IS deletion.  Deletion of the IS by itself lowered 
transcriptional activity of the hs1,2 enhancer, as previously seen, but with the Oct 
additionally mutated there seems to be a dramatic increase in activity (Fig. 15).  It is 
possible that deletion of the IS and mutation of the Oct site together acquit the enhancer 


























Figure 14.  Mutations involving Oct increase transcriptional activity of the hs1,2 
enhancer.  CH12.LX cells were transiently transfected with α1A, α1AOctmut, 
α1AISdelOctmut or α1AISdel reporter plasmids. Transfected cells were either cultured in 
the absence of any additional treatment (naïve, NA) or treated for 24 h with 0.01% 
DMSO vehicle (0 nM TCDD) or TCDD (0.01-10.0 nM) in the absence or presence of 
LPS (0.1 µg/ml) stimulation.  C represents the LPS alone control.  A.  Luciferase enzyme 
activity (mean ± SEM, n=3) is represented on the y-axis as relative light units (RLUs) 
normalized to transfection efficiency.  B.  TCDD-induced activation is represented on the 
y-axis as fold change relative to the DMSO vehicle. Results (mean ± SEM) were 
generated from separate experiments (n=3 for each treatment group within each 
experiment).  Comparisons between treatment groups of the same plasmid were analyzed 
using a 1-way ANOVA followed by a Dunnett’s Multiple Comparison post test.  
Asterisks, “*”, “**” or “***”, denote significance compared to the corresponding vehicle 
control at p<0.05, p<0.01 or p<0.001, respectively.  Comparisons between reporter 
plasmids were analyzed using a 2-way ANOVA Bonferroni post test.  Daggers, “††” or 
“†††”, denote significant differences between reporter plasmids for each treatment at 
p<0.01 and p<0.001, respectively.  Vertical line also represents significance at p<0.001.  
> denotes synergistic activation by LPS and TCDD cotreatment compared to the 
activation of either treatment alone.  Results are representative of at least three 





























































































































































Figure 15.  Mutating the AP1.ETS site decreases hs1,2 transcriptional activity more 
than deletion of the IS.  CH12.LX cells were transiently transfected with VH, α1A, 
α1AISdel, α1AISdelOctmut or α1AAP1.ETSmut. Transfected cells were either cultured in 
the absence of any additional treatment (naïve, NA) or treated for 24 h with 0.01% 
DMSO vehicle (0 nM TCDD) or TCDD (10.0 nM) in the absence or presence of LPS 
(0.1 µg/ml) stimulation.  C represents the LPS alone control.  A.  Luciferase enzyme 
activity (mean ± SEM, n=3) is represented on the y-axis as relative light units (RLUs) 
normalized to transfection efficiency.  B.  TCDD-induced activation is represented on the 
y-axis as fold change relative to the DMSO vehicle. Results (mean ± SEM) were 
generated from separate experiments (n=3 for each treatment group within each 
experiment).  Comparisons between treatment groups of the same plasmid were analyzed 
using a 1-way ANOVA followed by a Dunnett’s Multiple Comparison post test.  
Asterisks, “*”, “**” or “***”, denote significance compared to the corresponding vehicle 
control at p<0.05, p<0.01 or p<0.001, respectively.  Results are representative of three 






































































The role of Pax5 in mediating TCDD-induced activity of the human hs1,2 enhancer 
 Pax5 (BSAP) is a transcription factor that plays a vital role in B-cell development 
and differentiation.  It is present in pro-B, pre-B and mature B cells yet absent in plasma 
cells.  Pax5 represses IgH expression by suppressing the 3’IgH RR and its natural loss in 
the plasma cell stage resultantly contributes to the activation of the murine 3’IgH RR and 
Ig expression (Singh and Birshtein, 1993; Neurath, 1994).  Opposite of the murine hs1,2 
enhancer, hs4 enhancer activity is upregulated by BSAP binding, which occurs in early B 
cell lineage (Mills et al., 1997).  The one BSAP site found in the mouse hs4 enhancer is 
not found in the human hs4 enhancer indicating its presence is unnecessary for human 
hs4 activation (Mills et al., 1997).  A previous study indicated inhibition of mouse hs1,2 
enhancer activity through collaborative binding involving BSAP sites, an octamer 
sequence, a G-rich sequence and possibly an NF-κB binding site (Michaelson et al., 
1996; Singh and Birshtein, 1996).  Altered binding of these same sites allows for 
activation of the mouse hs1,2 enhancer following the loss of Pax5 that occurs following 
B-cell activation (Singh and Birshtein, 1996). It is possible that absence of a Pax5 
binding site in the human hs1,2 enhancer may partially explain TCDD-induced inhibition 
of the mouse hs1,2 enhancer versus TCDD-induced activation of the human hs1,2 
enhancer.   
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  LPS stimulation of mouse B cells decreases Pax5 mRNA and protein levels and 
binding beginning at 48 hrs post-stimulation (Yoo et al., 2004).  When B cells are 
activated by LPS in the presence of TCDD, inhibition of the expected decrease in Pax5 
levels is observed beginning at 48 hrs post-stimulation (Yoo et al., 2004).  Disturbance in 
the downregulation of Pax5 by TCDD is also consistent with repression of IgH, Igκ and J 
chain mRNA, which provides evidence that Pax5 is a key player in TCDD-induced 
suppression of the IgM response (Yoo et al., 2004, Schneider et al., 2008). It is possible 
that a DRE site in the Pax5 promoter is mediating TCDD-induced effects.  Like mouse, 
Pax5 is similarly present in human (e.g. IM-9 B lymphoblasts). A previous study 
indicated the TCDD-induced AhR recognized a Pax5 site in the promoter region of the 
CD19 gene, but this was because of a DRE site contained within the Pax5 site (Masten 
and Shiverick, 1995). While Pax5 is seemingly involved in TCDD/AhR signaling in 
mouse, its role in human Ig production remains largely in question. 
 As expected, addition of the high-affinity Pax5 binding site to the human hs1,2 
enhancer demonstrated a repressor role by decreasing overall transcriptional activity of 
the enhancer (Fig. 7A).  Also, synergism from cotreatment of LPS and TCDD was not 
evident with α1A + Pax5 (Fig. 7A).  TCDD-induced fold-change activation of the human 
α1A, however, remained unaffected by the presence of the Pax5 binding site (Fig. 7B).  
Even though inhibition of hs1,2 enhancer activity by TCDD as seen in the mouse was not 
similarly demonstrated by the α1A + Pax5, Pax5 signaling is highly complex.  Not only 
does Pax5 interact with other transcription factors, as previously mentioned, but it can 
display dual functions in B lymphocytes or undergo alternative splicing (Pinaud et al., 
2011).  Pax proteins are also able to regulate responses by inducing conformational 
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changes to DNA so it is possible that the murine high-affinity Pax5 site by itself (i.e. 
without low-affinity Pax5) was not sufficient in generating TCDD-mediated inhibition of 
the human hs1,2 enhancer (Chalepakis, 1994; Epstein et.al., 1994). Furthering the current 
study by adding the low affinity Pax5 site of the murine hs1,2 enhancer to the α1A + Pax5 
would help rule out this possibility.  Also, transient transfections were conducted at 24 
hrs and LPS decreases Pax5 activity beginning at 48 hrs (Yoo et al., 2004).   Even though 
TCDD-induced activation remained unaffected between α1A and α1A + Pax5 in this study, 
the role of Pax5 in how TCDD differentially modulates the mouse and human hs1,2 
enhancer cannot be disregarded.   
 Mutation of the high-affinity Pax5 site in the mouse hs1,2 reporter plasmid was 
also attempted throughout the duration of this project, but efforts remained unsuccessful. 
Several different approaches were taken to improve problems with low transformation 
efficiency and sequencing failure, such as increasing amounts of parental template, 
dNTP, mutant primers and/or adjusting PCR conditions.  The size of the reporter plasmid 
(~9 kb) in conjunction with repetitive DNA regions may be generating problematic 
secondary structures that hinder mutant plasmid extension in the thermal cycling step.  
Sequencing of the mouse hs1,2 reporter plasmid has ensured its quality so future attempts 
would be worthwhile.   
 
Activation of the human polymorphic hs1,2 enhancer by TCDD is AhR-dependent 
 The mechanism of TCDD-induced toxicity has been most well-defined through 
the aryl hydrocarbon receptor signaling pathway.  Historically, this pathway has been 
mapped out with the TCDD/AhR complex binding DRE sites in the promoter or enhancer 
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regions of genes for drug-metabolizing enzymes.  By using the AhR antagonist, CH-
223191, it was confirmed that TCDD-induced activation of the human polymorphic hs1,2 
enhancer requires the AhR.  It still remains unclear whether the AhR is directly or 
indirectly involved in the pathway, since the receptor complex can directly bind DRE 
sites or alter DNA binding or expression of other transcription factors such as AP-1, NF-
κB and SP1 (Kobayashi, 1996; Tian et al., 1999; Suh, 2002).   
 Experimental outcomes show the magnitude of TCDD-induced fold change 
activation did not change between α1A, α1B and α1C.  However, the amount of overall 
transcriptional activity is dependent upon the number of IS present.  The reporter 
plasmids all experienced synergistic activation from cotreatment of LPS and 10 nM 
TCDD as well.  Either one invariant sequence is enough to drive activation of the 
enhancer by TCDD and/or one or more binding sites outside of the polymorphic is 
involved.   
 As previously noted, α1C does not have a conserved DRE or AP-1 site in the third 
IS so a mutant plasmid (α1CClinical) has been generated restoring both sites back to their 
respective, consensus sequences.  Transient transfection and analysis of this plasmid will 
further establish whether or not there is any correlation between number of IS and degree 
of TCDD-induced fold change.  Additionally, the third IS has been deleted from the α1C 
(IS3delα1C).  Evaluation of this mutant plasmid may show a decrease in basal and LPS 
levels as seen by the α1AISdel and α1BIS1del and further credit the IS for possessing a 
significant amount of transcriptional activity.  As such, individual mutation of 
transcription factor binding motifs of the human hs1,2 enhancer will better pinpoint 
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which sites are involved in TCDD-induced modulation of the enhancer and its overall 
activity.    
 
Involvement of the transcription factors of the invariant sequence in human hs1,2 
activity 
 The invariant sequence contains a DRE, AP-1, NF1 and NF-κB site flanked by 
SP1 sites on both ends of the polymorphism (Chen and Birshtein, 1997; Denizot et al., 
2001; Giambra et al., 2005; Fernando et al., 2012).  Activator protein 1 (AP-1) is a 
heterodimer protein composed of c-Fos and c-Jun while nuclear factor kappa B (NF-κB) 
is also a heterodimer protein composed of different members of Rel family transcription 
factors.  Both have been associated with altered binding or regulation by the AhR or 
TCDD (Tian et al., 1999; Suh et al., 2002).  In LPS-activated CH12.LX cells TCDD 
suppressed AP-1 binding to AP-1 recognition sites within the B lymphocyte-induced 
maturation protein-1 (Blimp-1) promoter, which was in concordance with suppression of 
Blimp-1 by TCDD (Schneider et al., 2009).  Blimp-1 is a critical regulator of B cell 
differentiation and also acts as a transcriptional repressor to Pax5.  Following this 
suppression by AP-1, Blimp-1 mRNA and DNA-binding activity within the Pax5 
promoter dysregulated Pax5 (Schneider et al., 2009).  In a different study, TCDD-treated 
guinea pigs showed changes in protein phosphorylation that were accompanied by 
increased AP-1 DNA-binding activity in liver tissue (Ashida et al., 2000).  Outcomes 
from these separate studies indicate that TCDD may downregulate or upregulate AP-1 
activities.   
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 NF-κB has been identified as a key regulator of the murine hs1,2 enhancer and 
physical interactions between the AhR and NF-κB have been demonstrated (Tian et al., 
2002; Michaelson et al., 1996).  Mutation of the NF-κB site from a murine hs1,2 
enhancer reporter construct increased or decreased enhancer activity in a cell-stage 
dependent manner thus suggesting an important role for κB binding proteins in 
modulating the hs1,2 enhancer (Michaelson et al., 1996). Also, EMSA-Western Analysis 
showed TCDD-induced binding of NF-κB/Rel proteins to a κB site with an overlapping 
DRE in the hs4 enhancer (Sulentic et al., 2000).  The potential for a check-and-balance 
relationship between the NF-κB and AhR pathway has further been demonstrated, which 
may occur through negative regulation when one receptor binds within the other 
receptor’s promoter (Tian et al., 2002)  
 In the current study mutation of the AP-1 site and NF-κB site increased basal and 
LPS levels of the α1A human hs1,2 enhancer (Fig. 11A and 12A).  Like the α1A, a TCDD-
concentration response was also observed with both the α1AAP1mut and α1ANFκBmut 
(Fig. 11A and 12A).  An increase in overall transcriptional activity caused by mutation of 
the AP-1 or NF-κB could mean that these sites naturally have repressor roles.  
Alternatively, other sites present in the enhancer (i.e. AP1.ETS, Oct, SP1, DRE, NF1) 
may compensate for any loss in transcription from the AP-1 or NF-κB site and overly 
adjust activity as a result.  Since the previously mentioned studies imply that AP-1 and 
NF-κB can be affected by the AhR and/or TCDD, it is reasonable to think that either one 
of these binding motifs are responsible for TCDD’s ability to activate the human hs1,2 
enhancer.  Outcomes from this study, however, suggest otherwise.  TCDD-induced fold-
changes of α1AAP1mut and α1ANFκBmut had slightly lower stimulated fold-changes 
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compared to the α1A.  This may suggest that the AP-1 and NF-κB binding-motifs each are 
one of several binding-motifs that coordinate TCDD-induced hs1,2 enhancer activation in 
stimulated CH12.LX cells in addition to repressing basal and stimulated enhancer 
activity.   
 Because slightly lower TCDD-induced fold changes resulted from mutation of the 
AP-1 and NF-κB sites, creating a plasmid from the α1A that has both of these sites 
mutated would be beneficial. A double mutant of the α1A containing a mutated DRE and 
NF-κB has already been created, but still needs to be tested. One study indicated the 
importance of multiple binding sites when it demonstrated that in addition to a DRE, an 
NF-κB site was involved in TCDD-induced regulation of Fas and FasL promoters (Singh, 
2007).  As such, plasmids containing mutations of two or more transcription factor 
binding sites would help tease apart the complexity of how TCDD induces the human 
hs1,2 enhancer.   
 At this time concluding remarks cannot be made about the role the DRE may play 
in modulating TCDD-induced activation of the human hs1,2 enhancer.  Nevertheless, a 
plasmid containing a mutated DRE site from the α1A (α1ADREmut) has been created and 
initial efforts are suggesting an increase in overall transcriptional activity with no 
difference in fold change.  Additional DREs do not seem to increase the magnitude of 
TCDD-induced fold change, but the AhR certainly mediates TCDD-induced activity as 
seen from antagonist experiments (Fig. 8B).  It may be that one DRE site is enough to 
drive TCDD’s activation of the hs1,2 enhancer or it simply has minimal involvement.  
Also, the IS DRE site may affect basal and LPS-induced transcriptional activity since 
overall hs1,2 enhancer activity increases with the number of IS (Fig. 8A).  Results from 
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transient transfections of the α1ADREmut will determine if the drop in transcription that 
resulted from deletion of the IS is related to the DRE site.     
 The NF1, also located within the α1A IS, has not yet been mutated.  Analysis of 
this binding motif is critical, because a complete and comprehensive study will have been 
performed on every IS binding site.  Deletion of an IS from the α1A and α1B showed a 
decrease in overall transcriptional activity whereas mutation of the AP-1 and NF-κB sites 
showed an increase.  Analysis of the DRE and NF1 site may better explain this 
contradictory outcome.  Upon individual evaluation of the NF-κB, DRE, AP-1 and NF1 it 
will also be known which sites impact overall transcriptional activity the most and how.  
Additional mutation studies will determine if the DRE and NF1 mediate TCDD-induced 
fold change of the human hs1,2 enhancer is substantially altered.  Following a thorough 
assessment of each IS binding-motif, greater care can be taken as to which combination 
of multiple binding sites should be mutated from the parental α1A.  At this time it seems 
that TCDD-induced modulation of the hs1,2 enhancer is not driven solely through one 
binding site, but rather two or more.         
 
Transcriptional role of binding-motifs located outside the invariant sequence 
 Located 5’ and furthest from the IS is an AP1.ETS binding site.  An earlier study 
identified binding of a novel DNA binding complex, nuclear factor of activated B cells 
(NFAB), to an AP1.ETS site of the mouse 3’IgH RR that supported enhancer activation 
following cross-linking of surface IgM (Grant et al., 1995).  Also, in a study involving a 
melanoma cell line, matrix metalloproteinase promoter activity was increased when an 
AP1.ETS site was formed from an AP-1 site adjacent to a polymorphic ETS element 
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(Villano et al., 2006).  Despite increased promoter activity, however, the ETS 
polymorphism did not alter TCDD-induced activity compared to the wildtype (Villano et 
al., 2006).  Outcomes from these studies certainly highlight potential for the human hs1,2 
AP1.ETS site to possess an active role in the enhancer’s activity.  Out of all of the 
individual binding sites mutated and analyzed thus far, mutation of the AP1.ETS site 
(α1AAP1.ETSmut) was the only one that showed a decrease in transcriptional activity of 
the hs1,2 enhancer when transiently transfected into CH12.LX cells (Fig. 13A).  A drop 
in luciferase activity in both unstimulated and LPS-stimulated cells underscores the 
importance this site has in mediating human hs1,2 enhancer activity.  Evaluation of the 
α1AAP1.ETSmut still showed that TCDD-induced fold change did not differ from the α1A, 
but α1A did experience more synergism (Fig. 13A and 13B).  
 Also located 5’ and outside the IS is an octamer (Oct) site, which has been less 
studied in regards to AhR or TCDD-induced modulation.  Nevertheless, NF-κB in 
combination with Oct transcription factors seem to contribute to the activity of the mouse 
hs1,2 enhancer in plasma cells while Pax5 is concurrently downregulated (Michaelson, 
1996).  Also, Oct binding sites are frequently found in AhR-sensitive genes suggesting a 
possible role in the AhR signaling network (Kel et al., 2004).  Mutation of the Oct site 
(α1AOctmut) resulted in an increase in overall transcriptional activity of the human hs1,2 
enhancer when transiently transfected into CH12.LX cells suggesting an innate repressor 
role of the enhancer’s activity (Fig. 14A).  Interestingly, the α1AOctmut showed a 
significantly higher degree of TCDD-induced activation when compared to the α1A, but 
this was only seen in unstimulated cells.  Under this circumstance, Oct may naturally 
hinder hs1,2 activation by TCDD when LPS is not involved.  When transiently 
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transfected cells are LPS-stimulated, however, there appears to be no differences in 
TCDD-induced fold changes between the α1AOctmut and α1A (Fig. 14B).  LPS signaling 
must somehow disturb the mechanism that was involved in the increased fold-change of 
α1AOctmut activation by TCDD experienced in unstimulated cells.   
 Interestingly, mutating the Oct site in conjunction with deletion of the IS from the 
α1A (α1AOctmutISdel) experienced more overall transcriptional activity than α1AOctmut 
(Fig. 14A).  The α1AOctmutISdel did not always experience consistent TCDD-induced 
activation and stimulated fold changes were on average lower than α1A (Fig. 14A, 14B 
and 15).  One of the binding sites deleted or mutated must certainly be responsible for 
TCDD-induced activation of the hs1,2 enhancer, since the only remaining binding site is 
the AP1.ETS.  Otherwise some sort of inconsistent compensating mechanism may be 
taking place.  The IS deletion could have allowed for the flanking SP1 sites of the IS to 
come together to create one functional SP1 site that together with the remaining AP1.ETS 
site may have generated a highly transcriptionally active reporter plasmid.  
 In regards to SP1, one study indicated a synergistic effect between AhR/ARNT 
and SP1, which increased the drug-inducible expression of CYP1A1 in a Drosophila cell 
line (Kobayashi, 1996).  Another study credited an SP1-based transcription mechanism 
for mediating TCDD-induced protein and mRNA expression of mucin-5AC in human 
bronchial epithelial cells and an immortalized cell line that was independent of the AhR 
(Lee et al., 2010).  It is possible that either of the two SP1 transcription factor binding 
sites play an important role in modulating the TCDD-induced activation of the human 
hs1,2 enhancer. As such, both the 5’ (α1ASP1.1mut) and 3’ (α1ASP1.2mut) SP1 sites have 
been mutated from the α1A.  Upon evaluation, these mutagenic plasmids will provide a 
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more in-depth analysis on how these sites affect human hs1,2 transcriptional activity or 
TCDD-induced modulation.    
Conclusion     
 Ultimately, it is difficult to pinpoint the transcription factor binding sites 
responsible for TCDD-induced modulation of the human hs1,2 enhancer.  Differences in 
the DNA sequence between the mouse and human hs1,2 enhancer and how they are 
oppositely modulated by TCDD certainly emphasizes the potential difficulty in 
translating mouse data to human-assessment.  While addition of the mouse Pax5 site to 
the α1A decreased the enhancer’s transcriptional activity, TCDD was still able to activate.  
The presence of two Pax5 binding sites in the mouse hs1,2 enhancer versus none in the 
human may still explain why TCDD inhibits mouse activity yet activates human.  The 
high-affinity Pax5 was added to the α1A in a way that best mirrored the mouse hs1,2 
enhancer, but changes in the double helix or secondary structures of the mutant plasmid 
may have somehow masked or overridden TCDD-induced inhibition.  Otherwise, the 
involvement Pax5 has in mouse hs1,2 enhancer activity and TCDD responsiveness could 
simply be unrelated or unnecessary in the human hs1,2 enhancer.    
 Based on the other binding sites that have been evaluated in this study (AP-1, NF-
κB, Oct, AP1.ETS), none seem to be the sole driving force behind TCDD’s ability to 
activate the human hs1,2 enhancer.  Mutation of the AP-1 and NF-κB site showed slight 
decreases in TCDD-induced fold-change activation, however, outcomes were not 
statistically significant.  It seems very likely that several transcription factors are 
simultaneously involved in mediating the effect of TCDD.  Even though deletion of the 
IS shows no change in TCDD-induced activation of the human hs1,2 enhancer, EMSA 
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analyses indicate that TCDD induces binding within the IS in LPS-stimulated CH12.LX 
cells (data not shown).  Future efforts will focus on isolating and identifying proteins 
bound to the IS by mass spectrometry.    
 Individual site mutations of AP-1, NF-κB and Oct increased human hs1,2 
transcriptional activity suggesting repressor roles while mutation of AP1.ETS lowered 
overall enhancer activity (Fig. 16).  The AP1.ETS site seems to control much human 
hs1,2 enhancer activity, since it is the only site thus far that has shown a drop in 
transcription when mutated.  Deletion of the IS lowered transcriptional activity as well, 
but again it is difficult to discern which IS binding site(s) is/are of cause (Fig. 16).  
Furthermore, deleting rather than mutating the IS could be creating an inauthentic 
outcome due to changes in the secondary structure.   It would be worthwhile to generate 
one plasmid where all the IS binding sites have undergone mutation in order to reinforce 
results.  So far it seems the AP-1 and NF-κB sites may be involved in TCDD-induced 
fold-change activation of the enhancer underscoring the likelihood of a complex network 
of interacting transcription factors. Like AP-1 and NF-κB, the Oct site also showed a 
drop in fold change, but only in LPS-stimulated cells thus exemplifying signaling 














Figure 16.  Overall transcriptional activity outcomes of deletion/mutagenic plasmids 
compared to the human α1A.  Up or down arrow means greater or less overall 


























 A number of limitations persist in this study in addition to those already reported.  
First, fold change calculations do not provide a tell-all tale to TCDD-induced regulation.  
Overall increases or decreases in TCDD-induced transcription translate into real effects, 
which is a different perspective than simply magnitude of fold change. Second, there may 
be transcription factors or binding sites present in the hs1,2 enhancer that have not been 
identified.  Enhancer activity and TCDD-induced regulation could possibly be driven 
through other unrecognized means.  Finally, it is uncertain how accurately this research 
reflects the endogenous human IgH. Not only are outcomes not in the context of 
chromatin, but transcriptional activity is based on reporter plasmids containing a human 
gene transfected into murine B cells.  While the CH12.LX cells have been used 
extensively and contain a functional AhR pathway, current efforts are being made to 
characterize and develop a human B cell line that can be ligand-activated.  In spite of 
these limitations, this study lays the groundwork for uncovering hs1,2 regulation. 
 Overall, the hs1,2 enhancer has an important role in 3’IgH RR functioning, so 
understanding how TCDD or other AhR-ligands modulate it will provide greater insight 
into how chemically-induced immunotoxic effects are mediated.  Also, its involvement in 
the severity and prevalence of a number of autoimmune diseases makes it an area of 
interest.  Teasing apart the mechanism at hand could ultimately lead to the manipulation 
of the many disease states associated with the 3’IgH RR and human hs1,2 enhancer. 
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